Related news from
Mon, 22 Apr 2024 20:35:00 +0000	Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) RICHMOND, Calif., April 22, 2024--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT
Mon, 25 Mar 2024 18:52:30 +0000	What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today One thing we could say about the analysts on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) - they aren't optimistic...
Fri, 22 Mar 2024 12:05:00 +0000	Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering RICHMOND, Calif., March 22, 2024--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24.0 MILLION REGISTERED DIRECT OFFERING
Thu, 14 Mar 2024 13:26:40 +0000	Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations Sangamo Therapeutics ( NASDAQ:SGMO ) Full Year 2023 Results Key Financial Results Revenue: US$176.2m (up 58% from FY...
Thu, 14 Mar 2024 11:23:03 +0000	Q4 2023 Sangamo Therapeutics Inc Earnings Call Q4 2023 Sangamo Therapeutics Inc Earnings Call
Wed, 13 Mar 2024 12:05:00 +0000	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results RICHMOND, Calif., March 13, 2024--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Wed, 13 Mar 2024 12:01:00 +0000	Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs RICHMOND, Calif., March 13, 2024--SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION & BRAIN TRANSDUCTION
Tue, 12 Mar 2024 22:30:00 +0000	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast RICHMOND, Calif., March 12, 2024--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Mon, 12 Feb 2024 13:05:00 +0000	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease RICHMOND, Calif., February 12, 2024--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA ALIGNMENT ON ABBREVIATED PATHWAY TO POTENTIAL APPROVAL AND EMA PRIME ELIGIBILITY FOR ST-920 IN FABRY DISEASE
Mon, 12 Feb 2024 13:02:04 +0000	With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence...
Mon, 05 Feb 2024 23:01:00 +0000	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile RICHMOND, Calif., February 05, 2024--SANGAMO THERAPEUTICS ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY DISEASE SHOWING SUSTAINED BENEFIT AND DIFFERENTIATED SAFETY PROFILE
Tue, 21 Nov 2023 13:49:03 +0000	Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky We can readily understand why investors are attracted to unprofitable companies. For example, although...
Fri, 03 Nov 2023 21:03:47 +0000	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and thank you for standing by. Welcome to the Sangamo Third Quarter 2023 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised […]
Thu, 02 Nov 2023 12:15:00 +0000	Sangamo to cut jobs again with planned business overhaul The gene therapy company will move headquarters and reduce its workforce by 40%, while seeking partners for its Fabry and cell therapy research.
Wed, 01 Nov 2023 23:05:55 +0000	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update Company focuses on neurology-focused genomic medicine, announces restructuring and workforce reduction
Wed, 01 Nov 2023 20:01:00 +0000	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results BRISBANE, Calif., November 01, 2023--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Thu, 26 Oct 2023 14:02:05 +0000	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 25 Oct 2023 20:15:00 +0000	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast BRISBANE, Calif., October 25, 2023--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Tue, 24 Oct 2023 06:01:00 +0000	Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) BRISBANE, Calif., October 24, 2023--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT
Wed, 20 Sep 2023 20:15:00 +0000	Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit BRISBANE, Calif., September 20, 2023--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit